Finch Therapeutics Group, Inc. (FNCH)
OTCMKTS
· Delayed Price · Currency is USD
10.80
-0.20 (-1.82%)
Dec 23, 2024, 4:00 PM EST
Finch Therapeutics Group Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | - | 0.11 | 0.86 | 18.53 | 7.72 | 10.15 |
| Revenue Growth (YoY) | - | -87.57% | -95.35% | 140.08% | -23.98% | - |
| Cost of Revenue | - | 7.2 | 52.86 | 57.28 | 33.14 | 23.86 |
| Gross Profit | - | -7.09 | -52 | -38.75 | -25.43 | -13.7 |
| Selling, General & Admin | 19.69 | 26.91 | 36.19 | 21.24 | 14.01 | 7.44 |
| Operating Expenses | 19.69 | 26.91 | 36.19 | 21.24 | 14.01 | 7.44 |
| Operating Income | -19.69 | -34 | -88.19 | -59.99 | -39.44 | -21.14 |
| Interest & Investment Income | 1.23 | 1.57 | 0.25 | 0.02 | 0.11 | 0.49 |
| Currency Exchange Gain (Loss) | - | - | - | - | 0 | - |
| Other Non Operating Income (Expenses) | 3.33 | 4.05 | 0.7 | -0.05 | - | 0.04 |
| EBT Excluding Unusual Items | -15.12 | -28.38 | -87.24 | -60.02 | -39.33 | -20.61 |
| Merger & Restructuring Charges | 0.19 | -3.82 | -2.42 | - | - | - |
| Impairment of Goodwill | - | - | -18.06 | - | - | - |
| Gain (Loss) on Sale of Assets | 0.02 | 0.64 | -0.01 | 0.03 | -0.01 | -0.14 |
| Asset Writedown | 32.9 | -13.14 | -6.93 | - | - | - |
| Other Unusual Items | 0.75 | -0.61 | - | 1.83 | - | - |
| Pretax Income | -14.17 | -78.22 | -114.65 | -58.16 | -39.34 | -20.75 |
| Income Tax Expense | - | -3.46 | - | - | - | - |
| Net Income | -14.17 | -74.75 | -114.65 | -58.16 | -39.34 | -20.75 |
| Net Income to Common | -14.17 | -74.75 | -114.65 | -58.16 | -39.34 | -20.75 |
| Shares Outstanding (Basic) | 2 | 2 | 2 | 1 | 0 | 0 |
| Shares Outstanding (Diluted) | 2 | 2 | 2 | 1 | 0 | 0 |
| Shares Change (YoY) | 0.41% | 0.94% | 21.65% | 381.31% | 11.64% | - |
| EPS (Basic) | -8.82 | -46.59 | -72.12 | -44.51 | -144.91 | -85.34 |
| EPS (Diluted) | -8.82 | -46.59 | -72.12 | -44.51 | -144.91 | -85.34 |
| Free Cash Flow | -18.04 | -31.51 | -77.03 | -83.12 | -33.96 | -18.33 |
| Free Cash Flow Per Share | -11.24 | -19.63 | -48.46 | -63.61 | -125.09 | -75.35 |
| Gross Margin | - | - | - | -209.08% | - | -134.95% |
| Operating Margin | - | -31777.57% | -10243.21% | -323.68% | -510.90% | -208.21% |
| Profit Margin | - | -69863.55% | -13315.45% | -313.84% | -509.66% | -204.39% |
| Free Cash Flow Margin | - | -29443.93% | -8946.92% | -448.50% | -439.98% | -180.47% |
| EBITDA | -19.51 | -32.48 | -82.69 | -57.68 | -38.65 | -20.66 |
| EBITDA Margin | - | - | - | - | - | -203.47% |
| D&A For EBITDA | 0.18 | 1.52 | 5.51 | 2.3 | 0.79 | 0.48 |
| EBIT | -19.69 | -34 | -88.19 | -59.99 | -39.44 | -21.14 |
| EBIT Margin | - | - | - | - | - | -208.21% |
| Revenue as Reported | - | 0.11 | 0.86 | 18.53 | 7.72 | 10.15 |
Source: S&P Capital IQ. Standard template. Financial Sources.